#202 Dementia Part 2: Gray Matters Segment

Most clinicians see dementia medications on the med rec, but many of us aren’t sure how much they actually help. In this episode we break down donepezil, memantine, and the new anti-amyloid drugs, and when to stop them. • Do cholinesterase inhibitors really work? • What should clinicians know about lecanemab and donanemab before referring patients? • How much benefit should we expect and for how long? • When should you deprescribe dementia medications? 🔹Sponsor: Caraway’s cookware set is a favorite for a reason. For 10% off, go to Carawayhome.com/CoreIM or use code CoreIM at checkout. 🔹Transcript and Shownotes 02:27 | Deep Dive 1: How do we deliver the news of a diagnosis of dementia? 09:41 | Deep Dive 2: Prescribing medications for cognitive decline 29:30 | Deep Dive 3: Patient-centered management for a patient with cognitive decline 35:46 | Deep Dive 4: Planning for an uncertain future Tags: CoreIM, Internal Medicine, Medical Education, Cognitive Screening, primary care, nurse practitioner, physician assistant Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out Quince: https://quince.com/coreim * Use code FIGSRX for a great deal: https://wearfigs.com Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy